Earnings Call · Q2 FY2025·2025-08-12

Q2 25EPS +92.11%·Rev n/aQ1 25EPS +43.18%·Rev n/aQ4 24EPS -18.35%·Rev n/aQ3 24EPS +11.11%·Rev n/a⚠ consensus missing

Spero Therapeutics, Inc. SPRO

Shai Biran — Chief Executive Officer

Esther P. Rajavelu — See Remarks

Timothy Keutzer — Chief Operating Officer

−18.0%1d on move date−18.4% vs SPY3d−19.1%5d−22.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SPRO calls or request research access.

More SPRO calls Browse calls Request research access